Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Moehler

Showing results (31-40 of 218) with videos related to

Pageof 22
Sort By:
Clinical Medicine. Oncology|September 6, 2011
Docetaxel as salvage therapy in highly pretreated and drug resistant gastrointestinal carcinomasMartin F Sprinzl, Sonia M Wytopil, Anja Dahmen, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 4, 2017
Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosisJan-Christopher Metzger, Daniel Wollschläger, Matthias Miederer, et al.
BMC Cancer|July 19, 2006
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case reportMartin F Sprinzl, Carl C Schimanski, Markus Moehler, et al.
Cancer Chemotherapy and Pharmacology|May 1, 2012
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell linesAnnett Mueller, Erika Bachmann, Monika Linnig, et al.
Gastrointestinal Endoscopy|July 10, 2012
Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptorMichael S Hoetker, Ralf Kiesslich, Mustafa Diken, et al.
Cancer Gene Therapy|May 28, 2003
Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cellsMarkus Moehler, Maja Zeidler, Joerg Schede, et al.
Frontiers in Oncology|May 14, 2014
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1Markus Moehler, Katrin Goepfert, Bernd Heinrich, et al.
Anti-Cancer Drugs|September 23, 2003
Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancerMarkus Moehler, Ulrike Haas, Juergen Siebler, et al.
Chemotherapy|April 26, 2003
Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort studyMarkus Moehler, Frank Gutzler, Silke Steinmann, et al.
Molecular Medicine Reports|April 8, 2011
Cetuximab-induced skin exanthema: Improvement by a reactive skin therapyCarl C Schimanski, Markus Moehler, Tim Zimmermann, et al.
Pageof 22

Showing results (31-40 of 218) with videos related to

Sort By:
Pageof 22
Clinical Medicine. Oncology|September 6, 2011
Docetaxel as salvage therapy in highly pretreated and drug resistant gastrointestinal carcinomasMartin F Sprinzl, Sonia M Wytopil, Anja Dahmen, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 4, 2017
Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosisJan-Christopher Metzger, Daniel Wollschläger, Matthias Miederer, et al.
BMC Cancer|July 19, 2006
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case reportMartin F Sprinzl, Carl C Schimanski, Markus Moehler, et al.
Cancer Chemotherapy and Pharmacology|May 1, 2012
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell linesAnnett Mueller, Erika Bachmann, Monika Linnig, et al.
Gastrointestinal Endoscopy|July 10, 2012
Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptorMichael S Hoetker, Ralf Kiesslich, Mustafa Diken, et al.
Cancer Gene Therapy|May 28, 2003
Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cellsMarkus Moehler, Maja Zeidler, Joerg Schede, et al.
Frontiers in Oncology|May 14, 2014
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1Markus Moehler, Katrin Goepfert, Bernd Heinrich, et al.
Anti-Cancer Drugs|September 23, 2003
Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancerMarkus Moehler, Ulrike Haas, Juergen Siebler, et al.
Chemotherapy|April 26, 2003
Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort studyMarkus Moehler, Frank Gutzler, Silke Steinmann, et al.
Molecular Medicine Reports|April 8, 2011
Cetuximab-induced skin exanthema: Improvement by a reactive skin therapyCarl C Schimanski, Markus Moehler, Tim Zimmermann, et al.
Pageof 22